Trials / Unknown
UnknownNCT04135235
Effect and Safety of Propofol Fumarate for Mother-to-child Blocking of Hepatitis B
The Effect and Safety of Propofol Fumarate for Mother-to-child Blocking of Hepatitis B
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 440 (estimated)
- Sponsor
- Beijing Ditan Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 35 Years
- Healthy volunteers
- Not accepted
Summary
This study is a prospective study. The subject will select 440 cases of pregnant women with high hepatitis B virus load, and one group will take maternal and child blockade treatment with propofol fumarate. One group will take tenofovir disoproxil fumarate. Broken treatment, compare the failure rate of maternal and child blockade and the incidence of maternal and child adverse events in the two groups, and explore the efficacy and safety of propofol flavuril for the treatment of hepatitis B mother-infant block.
Detailed description
This study was a prospective cohort study. Because propofolofofovir is not covered by medical insurance and is more expensive, and there are factors such as renal function damage and the risk factors that can not use tenofovir, it is difficult to conduct randomized controlled cases. The subject will select 440 cases of pregnant women with high hepatitis B virus load. After signing the informed consent form, according to the patient's wishes, one group will take the mother-infant blockade of propofol fumarate, and one group will take fumaric acid. In the case of maternal and child blockade of benifovir, the incidence of maternal and child block failure and the incidence of maternal and child adverse events were compared between the two groups, and propofol fumarate was used for maternal and child blockade of hepatitis B. The effectiveness and safety of the treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TAF | Propofol tenofovir fumarate |
| DRUG | TDF | Dipirofurate fumarate tenofovir |
Timeline
- Start date
- 2019-08-01
- Primary completion
- 2021-08-01
- Completion
- 2021-08-01
- First posted
- 2019-10-22
- Last updated
- 2019-10-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04135235. Inclusion in this directory is not an endorsement.